Core Viewpoint - The launch of the drug price registration system in China is a significant step towards establishing a global pricing framework for innovative drugs, enhancing the international competitiveness of Chinese pharmaceutical companies [1][3][6]. Group 1: Drug Price Registration System - The drug price registration system, initiated by the National Healthcare Security Administration, allows domestic and foreign pharmaceutical companies to independently declare drug prices, creating a comprehensive pricing archive [1][3]. - The system operates independently from provincial procurement platforms and follows principles of "one location acceptance, nationwide sharing, and global openness," which aids in building a globalized drug pricing system [1][3]. - The registration of prices does not alter the medication costs for insured and uninsured individuals [1]. Group 2: Support for Chinese Pharmaceutical Companies - The new system addresses the shortcomings in the pricing mechanism for innovative drugs, facilitating their entry into international markets and allowing for pricing that aligns with local payment systems [3][4]. - Companies like Yifan Pharmaceutical highlight that the system will provide substantial support for overseas expansion, allowing for a more accurate reflection of the true value of innovative drugs [4]. - The system enables companies to register prices according to international practices, providing verifiable pricing information to regulatory bodies and partners [4]. Group 3: Attracting Foreign Innovative Drugs - The establishment of the drug price registration system is expected to attract more high-quality foreign innovative drugs into the Chinese market, as multinational companies will be encouraged to participate in national healthcare negotiations [6][7]. - The system allows multinational companies to register prices independently in China, creating a clear distinction between market supply prices and negotiated healthcare prices, which enhances the certainty of market entry for innovative drugs [7].

Core Points - Jiangsu Hengrui Medicine Co., Ltd. has received the acceptance notice from the National Medical Products Administration for its drug application of injectable remimazolam tosylate [2] Group 1 - Drug Name: Injectable Remimazolam Tosylate [2] - Dosage Form: Injectable [2] - Acceptance Number: CXHS2500146 [2] - Application Stage: Market Approval [2] - Applicant: Jiangsu Hengrui Medicine Co., Ltd. [2] - Proposed Indication: Sedation during mechanical ventilation in intensive care [2]

恒瑞医药（600276）(01276)发布公告，关于回购公司A股股份的进展：2025年11月，公司通过上海证券 交易所交易系统以集中竞价交易方式回购股份97.99万股，已回购股份占公司总股本的比例为0.015%， 购买的最高价为人民币63.28元/股，最低价为人民币59.32元/股，已支付的总金额为人民币5978.85万元 (不含交易费用)。截至2025年11月30日，公司本次股份回购方案累计通过上海证券交易所交易系统以集 中竞价交易方式回购股份889.87万股，已回购股份占公司总股本的比例为0.13%，购买的最高价为人民 币70.00元/股，最低价为人民币59.32元/股，已支付的总金额为人民币5.95亿元(不含交易费用)。 ...

Core Viewpoint - Heng Rui Medicine (01276) has announced the progress of its A-share repurchase plan, indicating a strategic move to enhance shareholder value through share buybacks [1] Group 1: Share Repurchase Details - In November 2025, the company repurchased 979,900 shares through the Shanghai Stock Exchange, accounting for 0.015% of the total share capital, with a maximum purchase price of RMB 63.28 per share and a minimum of RMB 59.32 per share, totaling RMB 59.7885 million (excluding transaction fees) [1] - As of November 30, 2025, the cumulative repurchase amounted to 8,898,700 shares, representing 0.13% of the total share capital, with a maximum price of RMB 70.00 per share and a minimum of RMB 59.32 per share, totaling RMB 595 million (excluding transaction fees) [1]

Core Viewpoint - Heng Rui Medicine (01276) has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of injectable toremifene, indicating progress in its product pipeline [1] Group 1: Product Development - The injectable toremifene has been approved for indications including sedation and anesthesia during non-tracheal intubation surgeries and for induction and maintenance of general anesthesia [1] - The application for market approval is based on two key studies focused on sedation for mechanically ventilated patients in the Intensive Care Unit (ICU) [1] Group 2: Clinical Research - The HR7056-302 study is a Phase III clinical trial evaluating toremifene compared to standard first-line treatments for short-term sedation during critical care, involving 214 patients across 43 centers, led by Professor Guan Xiangdong from Sun Yat-sen University First Affiliated Hospital [1] - The HR7056-206 study is a multi-center Phase II clinical trial assessing toremifene for long-term sedation in critical care, with 24 patients enrolled from 18 centers, led by Professor Shen Feng from Guizhou Medical University Affiliated Hospital [1] - Both studies achieved their primary endpoints as expected [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has announced a share repurchase plan, indicating a strategic move to enhance shareholder value through buybacks [1] Summary by Categories Share Repurchase Details - As of November 30, 2025, the company has repurchased a total of 8.8987 million shares, which represents 0.13% of the total share capital [1] - The highest purchase price was RMB 70.00 per share, while the lowest was RMB 59.32 per share [1] - The total amount paid for the repurchased shares is RMB 595.2163 million, excluding transaction fees [1]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received the acceptance notice from the National Medical Products Administration for its drug application of injectable remimazolam tosylate, indicating progress in the drug approval process [1] Group 1: Drug Information - Drug Name: Injectable Remimazolam Tosylate [1] - Dosage Form: Injectable [1] - Acceptance Number: CXHS2500146 [1] - Application Stage: Market Approval [1] - Applicant: Jiangsu Hengrui Medicine Co., Ltd. [1] - Proposed Indication: Sedation during mechanical ventilation in intensive care [1]

Core Points - The launch of the China Drug Price Registration System aims to facilitate the globalization of Chinese innovative drugs and attract high-quality foreign drugs to the Chinese market, benefiting patients in China [1][4] - The system operates under a "one location acceptance, nationwide sharing, global openness" service mechanism, allowing pharmaceutical companies to independently declare and register drug prices [1][4] - The establishment of this system fills a gap in the national-level drug pricing disclosure framework in China, enhancing the credibility of registered prices compared to provincial systems [5] Group 1: System Overview - The China Drug Price Registration System (China Drug Registration) was officially launched on December 2, providing a platform for drug price registration and inquiry [1] - The system is a collaboration between the National Healthcare Security Administration and the Beijing Municipal Government, operated by a state-owned enterprise under a socialized operation model [1][4] - The registration process allows drug market authorization holders to voluntarily declare prices and is open for public inquiry, ensuring transparency [5] Group 2: Industry Impact - The system is expected to significantly impact the high-quality development of the pharmaceutical industry in China, aligning with the country's goal of building a healthy China and supporting the development of innovative drugs and medical devices [3][4] - By providing a platform for global price registration, the system helps Chinese pharmaceutical companies establish a comprehensive global pricing framework, enhancing the modernization of drug price governance [4][5] - The system's independent operation from provincial procurement platforms allows for a clearer distinction between market prices and negotiated prices under healthcare insurance [4][5]

证券之星消息，12月2日，医疗健康R（480016）指数报收于7315.52点，跌1.46%，成交161.03亿元，换 手率0.53%。当日该指数成份股中，上涨的有4家，济川药业以1.0%的涨幅领涨，下跌的有46家，泰格医 药以3.88%的跌幅领跌。 医疗健康R（480016）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sh603259 | 药明康德 | 13.66% | 89.42 | -3.12% | 2668.08 | 医药生物 | | sh600276 | 恒瑞医药 | 11.00% | 61.12 | -1.32% | 4056.66 | 医药生物 | | sz300760 | 迈瑞医疗 | 7.57% | 200.62 | -0.50% | 2432.40 | 医药生物 | | sh688271 | 联影医疗 | 4.27% | 128.71 | -1.97% | 1060.77 | 医药生物 | | sh600436 | 片 ...

根据公告，恒瑞医药注射用甲苯磺酸瑞马唑仑已获批的适应症包括用于非气管插管手术/操作中的镇静 和麻醉以及用于全身麻醉的诱导和维持。 北京商报讯(记者王寅浩宋雨盈)12月2日，恒瑞医药（600276）发布公告称，公司收到国家药品监督管 理局下发的《受理通知书》，公司注射用甲苯磺酸瑞马唑仑的药品上市许可申请获国家药监局受理，拟 定适应症为重症监护期间机械通气时的镇静。 ...